Carney complex (CNC) is a familial neoplasia syndrome that is associated with pituitary-associated hypersecretion of growth hormone (GH) (acromegaly). The underlying cause of pituitary GH hypersecretion and its management have been incompletely defined. OBJECTIVE: To provide biological insight into CNC-associated pituitary pathology and improve management, we analyzed findings in CNC patients who underwent transsphenoidal surgery. METHODS: Consecutive CNC patients at the National Institutes of Health with acromegaly and imaging evidence of a pituitary adenoma(s) who underwent transsphenoidal resection of tumor(s) were included. Prospectively acquired magnetic resonance imaging and biochemical, surgical, and histological data were analyzed. RESULTS: Seven acromegalic CNC patients (2 male, 5 female) were included. The mean age at surgery was 29.7 years (range, 18-44 years). The mean follow-up was 4.7 years (range, 0.2-129 months). Magnetic resonance imaging revealed a single pituitary adenoma in 4 patients and multiple pituitary adenomas in 3 patients. Whereas patients with single discrete pituitary adenomas underwent selective adenomectomy, patients with multiple adenomas underwent selective adenomectomy of multiple tumors, as well as partial or total hypophysectomy. All adenomas were either GH and prolactin positive or exclusively prolactin positive. Pituitary tissue surrounding the adenomas in patients with multiple adenomas revealed hyperplastic GH-and prolactin-positive tissue. CONCLUSION: CNC-associated acromegaly results from variable pituitary pathology, including a single GH-secreting adenoma or multiple GH-secreting adenomas and/or GH hypersecretion of the pituitary gland surrounding multiple adenomas. Although selective adenomectomy is the preferred treatment for cases of GH-secreting adenomas, multiple adenomas with associated pituitary gland GH hypersecretion may require partial or complete hypophysectomy to achieve biochemical remission.
F
irst described in 1985, Carney complex (CNC) is a rare, autosomal dominant, familial neoplastic syndrome that presents with dermatological, endocrine, and cardiac abnormalities. 1 Clinical manifestations of CNC include spotty skin pigmentary anomalies, endocrine overactivity, myxomas (skin, mammary, and cardiac), and nerve sheath tumors, including psammomatous melanotic ABBREVIATIONS: cAMP, 3 ,5 -cyclic adenosine monophosphate; CNC, Carney complex; GH, growth hormone; IGF-1, insulinlike growth factor 1 schwannomas. To date, >750 cases of CNC have been identified worldwide. 2, 3 Genetically, CNC is heterogeneous in expression and involves the tumor suppressors CNC1 (also called PRKAR1A; chromosome 17) and CNC2 (chromosome 2). [4] [5] [6] Due to the morbidity associated with the lesions and endocrine disorders in CNC, 7 serial screening of target organs and clinical evaluation, in conjunction with judicious intervention to treat specific disease manifestations, is critical.
Endocrine overactivity associated with CNC can result from a number of neoplasms, including pituitary adenomas, large-cell calcifying Sertoli cell testicular tumors, and thyroid adenomas. Growth hormone (GH) hypersecretion is a common occurrence in CNC patients and results in elevated serum GH and insulin-like growth factor 1 (IGF-1) in˜75% of CNC patients. 8 However, CNC-associated GH hypersecretion is not always indicative of pituitary adenoma formation on magnetic resonance imaging (MRI). 9 Gigantism or acromegaly develops in ∼10% of CNC patients with imaging evidence of a pituitary adenoma. 10, 11 Previous reports of isolated cases described GH and IGF-1 levels that are pathologically elevated years before a pituitary adenoma is identified on MRI. 8, 9 Although secretion of GH from a single pituitary adenoma underlies sporadic acromegaly cases, multiple factors appear to underlie GH hypersecretion in sporadic CNC cases, including singular or multiple pituitary adenoma(s). Consequently, the atypical features of pituitary-associated acromegaly in CNC indicate that biological features may dictate variable surgical management approaches. To better understand the biology and surgical management of CNC patients with associated acromegaly and imaging evidence of a pituitary adenoma, we analyzed imaging, biochemical features, surgical findings, and histology of affected patients.
METHODS

Patients
Consecutive CNC patients at the National Institutes of Health with acromegaly and imaging evidence of a pituitary adenoma(s) who underwent transsphenoidal resection of a tumor(s) between 1996 and 2016 were included. Patients provided written informed consent to undergo evaluation and care at the Clinical Center at the NIH. Clinical data were prospectively acquired from these patients and were described, in part, previously.
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Biochemical Testing
Patients were diagnosed with acromegaly based on clinical symptoms and established biochemical values of IGF-1 and GH (including during administration of an oral glucose tolerance test). Biochemical remission after surgery was defined as a random serum GH <1 or ≤0.4 ng/mL during oral glucose tolerance testing, combined with age-sex normalized IGF-1 levels. 12 Serum prolactin levels were measured immediately before surgery and in the follow-up after surgery.
Imaging
Patients underwent high-resolution, pre-and postcontrast, spin echo, and/or 3-dimensional gradient echo T1-and T2-weighted MRI of the pituitary.
Surgical Treatment
All patients underwent surgical exploration of the pituitary gland via a sublabial transsphenoidal approach. Upon discovery and identification of a discrete pituitary adenoma, complete resection was accomplished via circumferential dissection around the pseudocapsule of the tumor. 13 Similarly, if multiple adenomas were identified during inspection of the pituitary gland, circumferential removal of each of the adenomas using the pseudocapsule was used, unless the extent of disease required partial or complete hypophysectomy.
Histological Analysis
Resected specimens, including adenoma and any dura suspected of dural invasion, were fixed in formalin and embedded in paraffin. Sections 5 mm thick were subsequently obtained that were analyzed using routine hematoxylin and eosin staining, as well as reticulin and GH, luteinizing hormone, prolactin, and adrenocorticotropic hormone immunohistochemistry.
RESULTS
Patients
Seven consecutive CNC patients (2 male, 5 female) were identified with clinical and biochemical evidence of acromegaly as well as a pituitary adenoma(s) visible on MRI ( Table 1 ). All patients underwent transsphenoidal surgery for pituitary adenoma(s). The mean age at surgery was 29.7 years (range, 18-44 years), and the mean follow-up was 4.7 years (range, 0.2-129 months).
Imaging Findings
MRI of the pituitary gland demonstrated evidence of a single or multiple pituitary adenomas in all 7 patients (Table 1; Figures 1  and 2) . Although a single discrete pituitary adenoma was found in patients 2, 3, 5, and 7, multiple adenomas were identified on MRI in patients 1, 4, and 6. The mean size of discrete singular adenomas on MRI was 12.6 mm (range, 6-18 mm; Table 1 ).
Surgical Findings Single Adenomas
Consistent with MRI, patients 2, 3, 5, and 7 (Table 1) were found to have a discrete single adenoma during a comprehensive exploration of the pituitary gland. The adenoma in each of these patients was removed completely by circumferentially developing the plane between the adenoma pseudocapsule and the surrounding pituitary gland.
Multiple Adenomas
On MRI and during surgery, multiple pituitary adenomas were identified in patients 1, 4, and 6 (Table 1) . Patient 6 underwent discrete resection of 2 adenomas ( Figure 2 ). Based on the multiplicity and extent of adenomatous involvement in the pituitary gland in patients 1 and 4, a partial and a complete hypophysectomy were performed.
Biochemical Findings Biochemical Remission
Preoperatively, patients had clinical and biochemical findings consistent with acromegaly, including elevated GH, IGF-1, and the lack of oral glucose suppression of GH (Table 1) . Postoperatively, in all patients, substantial improvement of the biochemical measures of acromegaly was achieved (Table 1) . Elevated preoperative serum prolactin levels in 2 patients (patients 5 and 7, who had single adenomas) (Table 1) were reduced postoperatively.
Endocrine Function
Six patients remained at their preoperative endocrine status. Three of these patients had previously undergone bilateral adrenalectomy and had no cortisol secretion (patients 1, 3, and 6), and 1 patient (patient 3) treated for follicular thyroid cancer had hypothyroidism preoperatively. The patient who underwent total hypophysectomy (patient 4) experienced panhypopituitarism after surgery.
Complications
One patient (patient 2) had transient diabetes insipidus after surgery. 
FIGURE 3. Magnetic resonance imaging and histological features from a Carney complex case of acromegaly with multiple associated pituitary adenomas (patient 4; underwent total hypophysectomy). Postcontrast T1-weighted magnetic resonance imaging A reveals multiple hypoenhancing lesions consistent with adenoma (arrowheads). B Collage of immunohistochemical analysis after total hypophysectomy demonstrating multiple growth hormone-negative adenomas (light blue) surrounded by areas of normal and hyperplastic pituitary gland that are positive for growth hormone in a patient with elevated circulating growth hormone and insulinlike growth factor 1. The adenomas were positive for prolactin on immunohistochemistry (data not shown). Color version available online only.
Histopathological Findings Single Adenomas
Reticulin staining and immunohistochemical analysis revealed a pituitary adenoma in all 4 patients with single adenomas on MRI and at surgery (patients 2, 3, 5, and 7) ( Table 1) . Pathological features of all pituitary adenomas included disruption of the acinar cytoarchitecture with concurrent GH-and prolactinpositive immunohistochemistry (Table 2; Figure 1 ). Nontumorous pituitary tissue that was removed en route to the adenoma was available for 2 patients with single adenomas and was consistent with a normal pituitary gland, without hyperplasia.
Multiple Adenomas
Reticulin staining and immunohistochemical analysis revealed pituitary adenomas in all 3 patients with multiple adenomas (patients 1, 4, and 6; Table 1 ). The adenomas in 2 patients expressed both GH and prolactin (patients 1 and 6) (Figure 2) , whereas in patient 4, the multiple adenomas were positive for prolactin only, surrounded by zones of somatotroph hyperplasia (Figure 3) . The pituitary gland surrounding the adenomas in all 3 patients revealed expanded GH-and prolactin-positive acini consistent with mammosomatotroph hyperplasia (Figure 2 ; Table 2 ).
DISCUSSION
Current Study Clinical Findings
Many CNC patients have associated GH hypersecretion without imaging evidence of pituitary adenoma or other GHsecreting lesion. These patients are typically managed with somatostatin analogues until a pituitary lesion is identified on MRI. The CNC patients in the current study had clinical and biochemical findings consistent with acromegaly (Table 1) . MRI in these patients also revealed evidence of single or multiple pituitary adenomas that were confirmed by intraoperative exploration of the pituitary gland. Transsphenoidal resection of single adenomas or partial/total hypophysectomy was performed depending on the extent of disease. The resection of adenomas or hypophysectomy resulted in substantial endocrine improvement in all of the patients and in biochemical remission using current stringent criteria in 4 patients.
Histological Findings
Consistent with MRI and intraoperative findings, histopathological analysis revealed 2 distinct patterns of pathological changes, including single mammosomatotroph pituitary adenomas (4 patients) or multiple pituitary adenomas with concurrent mammosomatotroph hyperplasia (3 patients) ( Table 2 ). Although the pituitary gland of patients with solitary adenomas was normal, GH-and prolactin-positive pituitary hyperplasia was identified in patients with multiple adenomas (Figure 2) , including a patient with multiple prolactin onlypositive pituitary adenomas (Figure 3 ). Taken together, these histological findings indicate that multiple mechanisms may underlie GH hypersecretion associated with CNC and show that prolactin-positive pituitary adenomas (prolactin alone or coexpression with GH in adenomas) are also a frequent occurrence in CNC.
Mechanisms of GH Hypersecretion in CNC
The histological findings, specifically mammosomatotroph hyperplasia and adenomas found in these CNC cases, recapitulate pathological features recently identified in McCune-Albright syndrome, another genetic syndrome that frequently results in GH hypersecretion.
14 Similar to McCune-Albright syndrome, the presence of both a hyperplastic pituitary gland and adenomas indicates a continuum of pathological changes with GH-positive hyperplasia, likely representing incipient adenoma formation in CNC patients who are predisposed to tumor formation. However, unlike McCune-Albright syndrome (in which hyperplasia occurs in all patients with GH hypersecretion), the normal gland histology in CNC patients with single adenomas and biochemical remission after selective adenomectomy(s) indicate that pituitary hyperplasia does not contribute to elevation of GH or prolactin in these cases.
The biological basis for GH-secreting adenoma formation and pituitary gland mammosomatotroph hyperplasia in CNC patients is likely a mutation in the tumor suppressor gene CNC1 or CNC2. The CNC1 gene encodes protein kinase, 3 ,5 -cyclic adenosine monophosphate (cAMP)-dependent, regulatory subunit type I alpha (PRKAR1A), which is critical for cAMP signaling. 15 Thus, the abnormal regulation of cAMP mimics the effects of activating mutations of the G protein-cAMP pathway that underlies many sporadic tumors producing acromegaly. 16, 17 These mechanistic findings also may explain the similarities (cAMP alterations) in pituitary dysregulation between CNC and McCune-Albright syndrome patients. However, whereas the McCune-Albright syndrome effects on the pituitary gland result from a GNAS1 gene mutation that causes increased Gs-alpha expression and downstream cAMP generation, CNC-related pituitary effects are caused by enhanced downstream stimulation of cAMP. These differences may explain the differing pituitary features between the 2 disorders.
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Implications for Management
The histological, biochemical, imaging, and clinical features displayed by these patients provide a number of insights into the GH hypersecretion in CNC. Although nearly 75% of CNC patients have asymptomatic elevations of GH/IGF levels, most do not have evidence of a pituitary adenoma on MRI until later in life (third decade and beyond). 3 These findings may represent incipient adenoma formation within pituitary hyperplasia or early evidence of acromegaly caused by a discrete adenoma without imaging evidence of it, which is infrequently associated with sporadic cases of acromegaly. 19 The latter circumstance seems likely in CNC, as hyperplastic changes did not occur in cases of singular adenomas. Furthermore, it is consistent with the infrequent lack of imaging evidence of an adenoma in sporadic acromegaly, which is usually diagnosed years after symptom onset (with attendant tumor progression/growth) and unlike the surveillance/serial biochemical analysis that asymptomatic CNC patients routinely receive.
Based on the findings in these patients, GH hypersecretion in CNC can be caused by variable pituitary pathology visible on MRI. Single, discrete GH-secreting adenomas can underlie CNCassociated acromegaly. Complete selective adenomectomy in these cases is curative. Although no recurrences were noted in this cohort, longer term follow-up will be necessary to determine the incidence of new tumor development in this tumor predisposition syndrome with patients who undergo adenomectomy alone. CNC patients can also harbor multiple GH-positive adenomas and/or surrounding GH-positive pituitary hyperplasia. Resection of multiple discrete adenomas in CNC can be effective if the lesions secrete GH and can be removed completely. Nevertheless, it may not be feasible to identify and resect all the adenomas, and, in such cases, partial or complete hypophysectomy may need to be performed. Similarly, there are cases in which the multiple adenomas do not secrete GH, but surrounding pituitary GH hyperplasia underlies clinical acromegaly. In such cases with persistent GH hypersecretion, partial or complete hypophysectomy will be required for effective biochemical remission. The effects of alternative treatment for CNC-associated acromegaly remain undefined. Medical therapy, using pegvisomant, has been reported to control acromegaly in select patients with McCuneAlbright syndrome. 20 However, because surgical resection is often curative and medical therapy may require lifelong treatment, surgery should remain the treatment of choice for patients with CNC-associated acromegaly.
CONCLUSION
CNC-associated acromegaly can result from GH-secreting pituitary adenomas or from GH hypersecretion of the pituitary gland surrounding non-GH-secreting adenomas. Although selective adenomectomy is the preferred treatment for cases of GH-secreting adenomas, multiple non-GH-secreting adenomas with associated pituitary gland GH hypersecretion may require partial or complete hypophysectomy to achieve biochemical remission.
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